Literature DB >> 21159400

Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).

Lorraine Walsh1, Charles Gillham, Mary Dunne, Ian Fraser, Donal Hollywood, John Armstrong, Pierre Thirion.   

Abstract

We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it with a matched cisplatin group. The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis (p=0.014), skin dermatitis (p=0.0004), ≥10% weight loss (p=0.03), and enteral feeding requirement (p=0.05). This finding of enhanced toxicity is similar to recent publications. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21159400     DOI： 10.1016/j.radonc.2010.11.009

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  27 in total

1.  Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.

Authors:  Nicolas Dornoff; Christian Weiß; Franz Rödel; Jens Wagenblast; Shahram Ghanaati; Nateghian Atefeh; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2015-05-25       Impact factor: 3.621

2.  Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Nadeem Riaz; Eric Sherman; Lawrence Koutcher; Lauren Shapiro; Nora Katabi; Zhigang Zhang; Weiji Shi; Mathew Fury; Richard Wong; Suzanne Wolden; Shyam Rao; Nancy Lee
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

3.  Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-25       Impact factor: 2.503

4.  Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.

Authors:  Antonin Levy; Pierre Blanchard; Sara Bellefqih; Nacéra Brahimi; Joël Guigay; François Janot; Stéphane Temam; Jean Bourhis; Eric Deutsch; Nicolas Daly-Schveitzer; Yungan Tao
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

Review 5.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

6.  Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).

Authors:  Lauren Q Shapiro; Eric J Sherman; Nadeem Riaz; Jeremy Setton; Lawrence Koutcher; Zhigang Zhang; Weiji Shi; Matthew G Fury; Suzanne L Wolden; David G Pfister; Luc Morris; Nancy Lee
Journal:  Oral Oncol       Date:  2014-08-11       Impact factor: 5.337

7.  Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.

Authors:  Julien Roman; Gurvan Dissaux; Maelenn Gouillou; Yves Gobel; Gael Potard; Jean-Christophe Leclere; Virginie Conan-Charlet; Dorothy Gujral; Ronan Abgral; Briac Guibourg; Olivier Pradier; Ulrike Schick
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

8.  A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.

Authors:  Jiayi Huang; Andrew M Baschnagel; Peter Chen; Gregory Gustafson; Ishmael Jaiyesmi; Mitchell Folbe; Hong Ye; Jan Akervall; Daniel Krauss
Journal:  Int J Clin Oncol       Date:  2013-03-12       Impact factor: 3.402

9.  Use of cetuximab in combination with pulsed reduced dose-rate radiotherapy in a patient with recurrence of nasopharyngeal carcinoma in the neck.

Authors:  Guang-Hui Li; Bo Zhu; Fan Yang; Chuan-Kun Ma; Ding-Qiang Yang
Journal:  Exp Ther Med       Date:  2012-03-05       Impact factor: 2.447

Review 10.  Treatment of older patients with head and neck cancer: a review.

Authors:  Noam A VanderWalde; Mary Fleming; Jared Weiss; Bhishamjit S Chera
Journal:  Oncologist       Date:  2013-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.